Chilean Healthcare NGOs Release Adaptation of Exhaustive Canadian Obesity Guidelines
Chile launches evidence-based approach to obesity care rooted in Canada’s watershed 2020 clinical practice guidelinesEDMONTON, Alberta, Nov. 14, 2022 (GLOBE...
Neurology
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab...
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
Vaxcyte to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
BURNABY, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective AgonistTOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei...
electroCore to Announce Third Quarter 2022 Financial Results on November 3
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health,...
Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,...
Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease
SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease...
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
Avicenna Academy Avicenna AcademyThe education portal provides modules, case studies and other resources related to medical cannabis for Health Care...
electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today...
Assure Holdings Performs First Neuromonitoring Case in New Jersey
DENVER, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease...
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,...
IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana
New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A.,...